中大職務
- 醫學院助理院長 (醫療系統)
- 葉氏家族基金腫瘤學教授
- 腫瘤學系教授
專業範疇
- 內科腫瘤科
教育及資歷
MBBS (HKU), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond), MD (CUHK)
專注研究
- 肝胰膽癌和神經內分泌腫瘤的臨床研究
更多資訊
獎項及榮譽
- 香港內科醫學院Young Investigator Award, 2008
- 香港內科醫學院 Best Thesis Award Gold Medal, 2007
專業服務
- Journal of Hepatology副編輯
- Asia-pacific Journal of Clinical Oncology副編輯
- The International Liver Cancer Association教育委員會主席
- 大學教育資助委員會生物學及醫學學科小組委員（優配研究金及其他個人研究資助計劃）
中大教學職務
- 腫瘤學系醫學6年級教育統籌
- 香港中文大學威爾斯醫院醫療中心執行委員會委員
部分論文 (只有英文版本)
- Chan, S.L., Cheng P.N.M., Liu A.M., Chan, L.L., Li, L., Chu, C.M., Chong, C.C.N., Lau, Y.M., Yeo, W., Ng, K.K.C, Yu, S.C.H., Mok, T.S.K., Chan, A.W.H. A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. Investigational New Drug. 2021; 39(5): 1385-1382. PMID: 33856599.
- Bruix, J., Chan, S.L., Galle, P., Rimassa, L., Sangro, B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. Journal of Hepatology. 2021; 75(4):960-974. PMID: 34256065.
- Chan, S.L., Wong, L.L., Chan, K.C.A., Chow, C., Tong, J.H.M., Yip, T.C.F., Wong, G.L.H., Chong, C.C.N., Liu, P.H., Chu, C.M., Wong, V.W., To, K.F., Reeve, H.L., Chan, A.W.H. Development of a novel inflammation-based index for hepatocellular carcinoma. Liver Cancer. 2020; 9(2): 167-181. PMID: 7206612.
- Kwong, T.T, Wong, C.H., Zhou, J.Y., Cheng, A.S.L., Sung, J.J.Y., Chan, A.W.H., Chan, S.L.* Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade. JHEP Reports. 2020; 3(2): 10022 PMID: 33604533 (*corresponding author)
- Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y., Park, J.W., Blanc, J.F., Bolondi, L., Klumpen, H.J., Chan, S.L., Zagonel, V., Pressiani, T., Ryu M.H., Venook, A.P., Hessel, C., Borgman-Hagey, A.E., Schwab, G., Kelley, R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. New England Journal of Medicine. 2018; 379 (1): 54-63. PMID: 29972759.
- Chan, S.L., Yeo, W., Mo, F., Chan, A.W., Koh, J., Li, L., Hui, E.P., Chong, C.C.N., Lai, P.B.S., Mok, T.S.K., Yu, S.C. A Phase 2 Study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer. 2017; 123(20): 3977-3985. PMID: 28640364.
- Chan, S.L., Mo, F., Johnson P., Li, L., Tang, N., Loong, H., Chan, A.W.H., Koh, J., Chan, A.T.C., Yeo, W. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatololgy. 2015; 30(10):1529-35. PMID: 25968302.
- Chan, S.L., Mo, F., Johnson, P.J., Siu, D.YW., Chan, M.H.M., Lau, W.Y., Lai, P.B., Lam, C.W.K., Yeo, W. Yu, S.C. Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford). 2014; 16(4): 366-372. PMID: 23980880.
- Chan, S.L., Mo, F.K., Wong, C.S., Chan, C.M., Leung, L.K., Hui, E.P., Ma, B.B., Chan, A.T., Mok, T.S., Yeo, W. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012.118:3984-398 PMID: 22180222.
- Chan, S.L., Mo, F., Johnson, P.J., Hui, E.P., Ma, B.B., Ho, W.M., Lam, K.C., Chan, A.T., Mok, T.S., Yeo, W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiological response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. Journal of Clinical Oncology. 2009; 27: 446-452. PMID: 19064965.